Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.55 |
| ▸ | IDH1 | O75874 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19838636 | 0.85 | HDAC1 (0.52) | GPR119IDH1HDAC1GRM2PARP1 | |
| SCHEMBL19838635 | 0.85 | HDAC1 (0.52) | GPR119IDH1HDAC1GRM2PARP1 | |
| SCHEMBL652816 | 0.81 | GPR119 (0.56) | GPR119CHRNB2CHRNA4GRM5GRM1 | |
| SCHEMBL18837987 | 0.79 | GPR119 (0.50) | GPR119IDH1HDAC1GRM2KCNK3 | |
| SCHEMBL18838040 | 0.78 | GPR119 (0.49) | GPR119IDH1HDAC1GRM2KCNK3 | |
| SCHEMBL38661622 | 0.76 | GPR119 (0.52) | GPR119IDH1HDAC1GRM2GRM1 | |
| SCHEMBL22919195 | 0.75 | AR (0.61) | GPR119IDH1HDAC1GRM2 | |
| SCHEMBL30818801 | 0.75 | PARP1 (0.54) | GPR119HDAC1PARP1 | |
| SCHEMBL654477 | 0.75 | GPR119 (0.71) | GPR119CHRNB2CHRNA4GRM5GRM1 | |
| SCHEMBL1449629 | 0.75 | GPR119 (0.64) | GPR119IDH1HDAC1GRM2KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1359152-B1 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LAB (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7265115-B2 | Diazabicyclic CNS active agents | ABBOTT LABORATORIES (US) | 2007-09-04 | — | — | US | disclosed |
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1359152-A2 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LABORATORIES (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1147112-B1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LAB (US) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225268-A1 | Diazabicyclic CNS active agents | GABRE, GRIN1, CNTN1 | GPR119 343/4885IDH1 1174/4885HDAC1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.